Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing 17.11.19 | Navit Zomer
This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices 15.05.19 | Hezi Sternlicht, Ran Abramson, and Tomer Ganon
Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI 02.05.19 | Hezi Sternlicht
Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement 16.04.19 | CTech
Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq 24.01.19 | Lilach Baumer
Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars 08.01.19 | Lilach Baumer and Hezi Sternlicht
Teva Restructuring Cuts Deep into Israel’s Pharma Job Market, Exports 07.01.19 | Amitay Gazit and Dror Reich